Hope Biosciences

Japan has cautiously granted a conditional, global-first approval to SanBio Co., Ltd ’s autologous mesenchymal stem cell (MSC)-based therapy Akuugo (vandefitemcel; SB623) for traumatic brain injury (

Neurological disorders account for roughly 45% of rare diseases; and 85% of rare and ultra-rare disease trace back to a single gene defect. Given this, the potential for regenerative therapies to bene

COVID-19 may solidify Australian biotech Mesoblast Limited ’s position at the forefront of the development of stem cell therapies as FDA-regulated biologic products, giving a potential second use for

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in